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To investigate whether specific T-cell populations are 
overrepresented in tumor-infiltrating lymphocytes 
(TIL) in skin cancer, we determined the T-cell receptor 
(TCR) diversity in biopsy specimens of basal cell car-
cinoma and squamous cell carcinoma. Immunostain-
iug of tissue sections indicated that the majority of T 
cells expressed apTCRs. To assess diversity of the TCR 
p chain, RNA was isolated directly from the tumor 
specimens and peripheral blood mononuclear cells 
(PBMC) from the same patient, cDNA was synthe-
sized, and variable (V) p chain gene usage was deter-
mined by the polymerase chain reaction (PCR). In 
each basal cell (n = 11) and squamous cell (n = 7) car-
cinoma studied, several Vp families were overrepre-
sented in TIL versus PBMC, in that they accounted for 
greater than 5% of the repertoire in TIL and were at 
least 2% higher in TIL than in PBMC. The predomi-
nant Vp gene segments overrepresented in TIL gener-
T cells are believed to be pivotal in the course of the most common skin cancers, basal cell carcinoma (BCe) and squamous cell carcinoma (SCe). By im-munohistochemistry, it has been demonstrated clearly that T cells are a I2rominent component of the 
infiltrate in and around these tumors [1] . The resolution of an in-
completely excised BCC tumor [2] and a cutaneous SCC variant [3] 
is thought to be dependent upon this local T-cell response. Further-
more, treatment of BCC with intralesional interferon-a, inter-
feron-y, and interleukin-2, and of SCC with interferon-a leads to 
recruitment of T cells with concomitant tumor regression [4 - 9]. 
Immunosuppressed individuals, in contrast, develop increased 
numbers of BCC and SCC [10,11]. 
The role of T cells in mediating such antitumor responses is 
believed to depend on the recognition of tumor-specific antigens. 
The ability of T ceJIs to recognize antigen is conferred by a cell 
surface receptor, the T-cell receptor (TCR). The diversity of the 
TCR repertoire, and hence the ability to recognize a wide range of 
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ally differed from individual to individual. Simulta-
neous comparison of the V p repertoire of TIL to that of 
uninvolved skin and PBMC from the same individual 
revealed preferential expression ofVP families within 
the TIL in three of five basal cell and four of four 
squamous cell carcinomas. Again, the predominant 
V ps differed from individual to individual. Compari-
son of the TCR repertoire in uninvolved skin versus 
PBMC did indicate that some Vp families were over-
expressed in the resident T-cell compartment in skin, 
although the overrepresented families were not con-
stant from individual to individual. These data indi-
cate the selective concentration ofT cells bearing spe-
cific ap TCRs in the local immune response to basal 
cell and squamous cell carcinomas. Key words: antigen 
receptor/repertoire/polymerase chain reaction. ] Invest Der-
matoi103:751-757,1994 
antigens, is generated by recombination of variable (V), diversity, 
and joining m gene segments as well as nucleotide segment addi-
tions and deletions at the V-J junction. 
In this study, we set out to identify populations of tumor-infil-
trating lymphocytes (TIL) that may represent a specific T-cell re-
sponse to skin cancer. To determine the nature of the local T-ceII 
response, we compared the TCR Vp repertoire of TIL from BCC 
and SCC to that of peripheral blood mononuclear cells (PBMe) 
and normal skin from the same donor. We hypothesized that find-
ing a limited or skewed Vp repertoire within the TIL of tumors 
compared to that ofPBMC and uninvolved skin of the same patient 
would indicate T-cell recognition of a limited set of antigens, either 
tumor specific or autologous antigens. On the other hand, if the V p 
repertoire of TIL was similar to that ofPBMC and uninvolved skin, 
then the immune response may be directed against a large number of 
antigens or be nonspecific. 
MATERIALS AND METHODS 
Patients Bec and sce tissue specimens (approximately 4 mm3) were 
obtained from excisional biopsies performed during Mohs micrographic 
surgery. All specimens were obtained with informed consent. All cases were 
newly diagnosed primary tumors verified by standard histopathologic cri-
teria. Typical Bec and SCC tumors were used, i.e., they were not treated 
previously, the majority were of the nodular type, and they were of nonag-
gressive histologic appearance. 
Uninvolved skin was obtained from a site distal to the tumor and was 
histologically normal. Specimens were embedded in OCT medium (Ames 
Co., Elkhart, IN), snap frozen in liquid nitrogen, and stored at -70·C until 
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sectioning. Heparinized venous blood was obtained simultaneously with the 
tumor and uninvolved tissue specimens. 
Immunostaining Immunostaining was performed on frozen sections to 
identify cxp and yJ populations. Frozen sections (3 - 5 11m) were mounted on 
poly-L-lysine-coated slides. acetone fixed. and blocked with normal goat 
serum before undergoing 30-min incubations with the primary monoclon~l 
antibody. TCR-specific monoclonal antibodies include the following specI-
ficities: CD3 (Leu 4. Becton Dickinson. 1:100). TCR cxp (JJF1 prOVided by 
M. Drenner. 1:100). and TCR 15 (TCR 151. provided by M: Brenner. 1.:100). 
The slides next were incubated with biotinylated horse anti-mouse antibody. 
stained using the avidin/biotin complex Elite system (Vector Laboratories. 
Burlingame. CAl. and incubated with the 3-amino-9-.ethylcarbazole sub-
strate. The slides were washed in phosphate-buffered sal1l1e between 1I1cuba-
tions. counterstained with hematoxylin. and then mounted in glycerine and 
gelatin. Staining was . quantified by averaging the number of positively 
stained cells counted III three lugh-power fields by two I11dependent ob-
servers. 
Isolation of RNA Total RNA was isolated from tissue sections and 
PBMC by the method of Chomczynski and Sacchi [12]. To facilitate rapid 
lysis of the cells isolated from tissue. 20 X 5-llm sections were added to 
guanidinium isothiocyanate solution. PBMC (5 X 106) were isolated by 
Ficoll-paque (Pharmacia. Piscataway. NJ) density gradient centrifugation 
and dissolved directly in guanidinium isothiocyanate. To eliminate contam-
ination of genomic DNA. the samples were subjected to DNAse 1 treatment 
(Promega Corp .• Madison WI) for 30 min at 37 °C. RNase inhibitor 
(Boehringer Mannheim Corp .• Indianapoli s. IN) was present during all 
enzymatic manipulations of RNA. 
eDNA Synthesis cDNA was synthesized from 1 to 10 Ilg of total RNA by 
reverse transcription . mRNA was incubated at42°C for 1 h ina final volume 
of 50 111 containing 1 Ilg of oligo d(T),2_,B primer (Pharmacia). 500 11M 
dNTPs (Pharmacia). and AMV reverse transcriptase (Bethesda Research 
Labs. Gaithersburg. MD) at 1 U/Ilg RNA. 
Polymerase Chain Reaction (PCR) PCR analysis of the V p TCR rep-
ertoire was accomplished using oligonucleotide primers to ampl ify specific 
Vp gene segment$. The method employed was modified slightly from Der-
Simonian et at [13]. Each reaction contained one of 22 oligonucleotides. 
specific fora particular Vpfamily or subfamily. paired with a Cpprimer. The 
Cp primer was chosen for specific sequences. invariant between the CPl and 
C[J2 genes. PCR amplification of individual Vp cDNAs with paired V p and 
Cp primers was expected to yield product of about 260 base pairs in length. 
PCR amplification was performed using a DNA thermocycler (Perkin-
Elmer. Norwalk. CT) employing a 35-cycle program consisting of 45 sec-
onds of denaturation at 94 ° C. followed by 1 min at 65 ° C. The sensitivity 
was increased by extending the annealing/extension time 2 seconds per 
cycle. making the conditions on the final cycle 45 seconds at 94 ° C and 2 
min. 10 seconds at 65 °C. PCR buffer (Promega) was supplemented with 
Mg++ to a final concentration of 2.5 mM. All four deoxynucleotides were 
used at 200 11M. with 20 pM of each oligonucleotide and 2 U of Taq 
polymerase (Promega) included per 25-111 reaction . 
Radioactive Hybridization of PCR Product To confirm that the 
bands visible upon ethidium bromide staining correspond to amplified Vp 
genes. and to compare the occurrence of various TCR subpopulations. PCR 
products were transferred to Hybond-N nylon membranes (Amersham. Ar-
lington Heights. IL) following electrophoresis and hybridized with a rad io-
active probe. Some samples were denatured with 0.4 N NaOH and trans-
ferred directly to Hybond N using a Biodot SF slot blotter (Bio-Rad 
Laboratories. Richmond. CAl· The probe was another Cp oligonucleotide. 
labeled at the 5' end by T4 polynucleotide kinase (Boehringer Mannheim 
Biochemicals) and 32P_yATP (7000 Ci/mM. ICN. Costa Mesa. CAl. com-
plementary to sequences internal to the sequence recognized by the Cp 
oligonucleotide used for PCR amplification. 
PCR products were quantified using a radioanalytic imaging system (Au-
tomated Microbiology Systems Inc .• San Diego. CAl. Gels were scanned for 
1 to 3 h. and we determined the amount of radioactivity bound by all the 
V p-amplified material. the background. as well as that present in anyone 
lane. The relative intensity of individual bands was expressed as the number 
of counts present in anyone V P family divided by the total counts present in 
the total repertoire surveyed. 
RESULTS 
To identify specific T cells in the local immune response to skin 
cancer. we examined TCR gene expression in DCe. We anticipated 
that antigen-specific T cells would be selected clonally and undergo 
local clonal expansion. and thereby be identifiable as an overrepre-
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Figure 1. The majority of TIL express cxp TCR. The percentage of 
lymphocytes bearing cxp and yJ TCR in TIL of BCC using TCR-specilic 
monoclonal antibodies accordin g to immunoperoxidase staining of frozen 
biopsy specimens. 
sented TCR population within tumors as compared to PDMC from 
the same donor. 
TCR ap and yo Populations in TIL of BCC Information re-
garding the major TCR population in the local immune response to 
DCC was obtained using monoclonal antibodies in cOrUunction 
with immunoperoxidase staining. The majority ofTILs were found 
to be CD3+ (data not shown). In seven of nine tumors examined. yo 
T celis, stained with TCR 01, averaged less than 2.5% of the TIL 
(Fig 1). cx/3T cell s clearly accounted for the majority of TIL. These 
results suggest that a/3. and not yo, T cells play the major role in the 
local immune response to BCC. Similar results were found for SCC 
(data not shown) . 
PCR Analysis of the Vp Repertoire in BCC To identify 
whether any a/3 T-cell populations were concentrated selectively in 
BCC, we compared the TCR /3 chain repertoire of TIL to PBMC 
obtained simultaneously from the same individuals. To analyze the 
TCR /3 chain repertoire. we used PCR to amplify V/3 genes ex-
pressed by the TIL within DCC tumors. These repertoires are com-
pared in Table I. Those V/3 families that accounted for 5% or more 
of the repertoire in TIL and that were at least 2% greater in TIL 
versus PDMC are noted. In all 11 patients. one or more V/3 families 
were found to be overrepresented in TIL compared with PBMe. 
No V/3 family was overrepresented consistently in all the DCC 
studied. However. V/33 and V/36.1- 6.4 were overrepresented in six 
of the 11 BCC studied. and V/36.6/6.7 was overrepresented in five 
of the seven DCC in which the V/3 was studied. 
Another potential influence upon the V/3 repertoire in TIL of 
BCC is the TCR repertoire of the resident T-cell population in skin. 
To address this issue. we obtained a small portion of uninvolved skin 
from five patients at the time of cancer surgery. PCR amplification 
was performed on cDNA derived from uninvolved skin with the 
individual V /3 primers (Table II) . Comparison of the V /3 repertoire 
in TIL to the repertoires of PBMC and uninvolved skin revealed a 
skewed V/3 repertoire in BCC in three of five donors. In patient C. 
V/33. V/36.6/6.7. and V/313 .2/13.3 were overrepresented in TIL 
compared to both PBMC and uninvolved skin. In patient J, V/312. 
V/314. and V/315 were overrepresented in TIL compared to PBMC 
and uninvolved skin. In patient K. V/35.2. V/311. and V/312 were 
predominant in DCe. In patient E and in patient G, no V/3 family 
was overrepresented in DCC compared with both TIL and unin-
volved skin. These data indicate that the skewing of the V/3 reper-
toire in BCC versus PBMC is somewhat dependent on the TCR 
repertoire of uninvolved skin from the same donor. 
TCR VpRepertoireinSCC AsimilaranalysisofTCR V/3gene 
usage was performed in SCC to determine whether any T-cell sub-
populations are concentrated selectively at the tumor site. Simulta-
neous examination of the V/3 repertoire in SCC versus PBMC re-
vealed that in each tumor. several V/3s accounted for at least 5% of 
the TIL repertoire and were overrepresented by at least 2% com-
Table I. TCR V P Family Repertoire in Basal Cell Carcinoma Patients' 
Patients 
A B C 0 E F G 
V/!, Lesion PBMC Lesion PBMC Lesion PBMC Lesion PBMC Lesion PBMC Lesion PBMC Lesion PBMC Lesion 
1 5.5 8.1 3.6 1.8 2 3 1.5 2.3 2.9 0.3 2.1 0.2 1.9 2.1 6.7 
2 3.9 3 1.2 0.5 2.4 1.1 1.8 1.2 2.4 1 1.1 0.5 0.9 0.3 7.3 
3 4.8 11 5.0 0.3 8.1 3.3 6.7 5.8 8 2.1 5.6 1.8 2.3 0.6 6.8 
4 3 2.4 2.7 14.5 5.7 5.3 5.1 7.2 5.9 6.4 5.7 4.9 4.3 5.5 1.1 
5.1 6.7' 3.7 6.2 3.0 5.3 4.9 6.1 5.7 4.6 7.9 4.4 10.3 4.3 6.9 9 
5.23 3.4 3.4 1.9 0.1 2.3 3.2 1.9 1.8 2.4 4.6 1.2 1 2.0 0.7 2.2 
6.1234 5 2.7 5.1 9.5 9.8 4.1 8.1 5.5 7.7 1.8 7.5 2.1 3.4 2.7 10.5 
6.589 14.9 10.6 13.9 14.3 9.1 8.2 11.3 11.2 7.6 4.5 10.7 8.4 17.2 31.1 NO' 
6.67 17.4 17.7 13.5 18.8 17.5 11.1 12.6 13.6 8.4 6.2 14.2 10.9 18.0 11.0 NO 
7 8.3 5.5 5.0 5.1 8.4 12.5 5.1 8.2 10.5 12.5 8.8 5 6.4 7.4 3.4 
8 3.2 4.8 7.1 17.7 4 7.8 5.2 5.7 5.5 12.3 12.1 1.7 8.5 7.5 10.4 
9 2.4 4 5.5 3.8 3.7 2.9 3.3 5.1 3.8 10.5 5.1 2.2 4.1 5.6 5.3 
10 0.9 0.5 0.6 0.2 1.1 0.7 0.9 1.2 1.9 4.4 0.9 0.7 0.6 0.7 0.5 
11 0.5 0.6 0.3 0.4 1.1 0.3 0.5 1.0 1.5 2.1 0.6 0.3 0.6 1.6 1.9 
12 1.1 1.4 1.7 1.8 0.7 2.5 3.0 2.0 3.1 2.1 3.7 1.5 2.9 3.7 11.8 
13.1 3.9 2.5 3.6 1.3 3 4 6.4 3.7 4 4.2 3.8 3.9 5.5 3.1 2.3 
13.23 3.2 5.2 1.7 0.4 6 2.9 4.8 2.2 3.8 5.1 2 0.5 3.6 2.2 1.3 
14 4.7 6.5 4.1 1.5 2 4.1 5.9 3.8 4.6 4.2 3.3 2.3 4.9 1.9 8.2 
15 1.7 1.1 9.1 2.0 1.7 1.8 1.3 0.8 1.6 1.4 1.2 1.9 0.9 0.4 2.6 
16 1.2 1 1.3 0.4 0.3 2 1.7 1.6 1 1.2 1.6 0.9 1.0 0.5 1.8 
17 0.6 0.4 1.4 1.0 1.5 1.8 1.3 2.1 1.5 1.4 1 0.3 3.1 2.0 2.7 
18 1.3 1 1.8 0.4 0.3 1.9 2.0 2.2 1.7 1.4 0.9 0.1 1.5 0.9 1.2 
19 0.2 0.6 0.4 0.4 0.4 0.5 0.4 2.9 1.4 0.5 0.6 0.3 0.6 0.2 0.7 
20 0.8 0.8 1.2 0.4 0.5 1.9 1.0 1.6 2 0.5 0.6 1.2 0.6 0.8 1.6 
21 0.2 0.2 0.8 0.2 1 1.6 0.5 0.2 0.7 0.3 0.4 0.6 0.3 0.4 NO 
22 0.3 0.4 0.5 0.1 0.3 1 0.7 0.5 0.4 0.2 0.3 0.1 0.1 0.1 NO 
23 0.6 0.7 0.1 0.1 0.5 1.8 0.6 0.4 0.4 0.5 0.2 0.1 0.4 0.1 NO 
24 0.1 0.2 0.6 0.1 0.3 0.8 0.5 0.4 0.7 0.5 0.2 0.2 0.3 0.1 NO 
• Values shown in this table are percentages of cpm present in correspondent Vp of the total cpm present in the repertoire surveyed. 
I Vps.23 = VpS.2/5.3; Vp6.1234 = Vp6. 1/6.2/6.3/6.4; Vp6.589 = Vp6.5/6.8/6.9; Vp6.67 = Vp6.6/6.7; Vp13.23 = VPt3.2/13.3. 
, Bold. Vb families in lesions representing more than 5% of the total repe.rtoire and greater tban 2% higher compared with PBMC from the same patient. 
J NO. not done . 
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Table II. TCR V P Family Repertoire in Basal Cell Carcinoma Patients, Including Analysis of Uninvolved Skina 
Patients 
C E G J K 
v/1 Lesion NS' PBMC Lesion NS PBMC Lesion NS PBMC Lesion NS PBMC Lesion NS PBMC 
1 2 2 3 2.9 2.1 0.3 1.9 2.3 2.1 7.2 7 12.5 4.1 3 2 
2 2.4 2.5 1.1 2.4 2.5 1 0.9 1.5 0.3 8.8 19.1J 7.2 6.4 16.8 2.1 
3 8.1< 3.1 3.3 8 8.1 2.1 2.3 2.9 0.6 8.2 75 2.3 6.5 6:3 2.8 
4 5.7 5.3 5.3 5.9 4.6 6.4 4.3 4.5 5.5 5.4 6 6.5 3 6 2.1 
5.1 5.3 5.7 4.9 4.6 3.9 7.9 4.3 3.4 6.9 6.4 6 15.3 4.3 3' 2.3 
5.23 2.3 2.2 3.2 2.4 1.6 4.6 2.0 2.2 0.7 4.4 5.3 4.3 5.7 0.2 2.9 
6.1234 9.8 8.9 4.1 7.7 6.1 1.8 3.4 5.8 2.7 3 10 6.3 9.5 24.8 20.3 
6.589 9.1 12.1 8.2 7.6 11 .2 4.5 17.2 8.6 31.1 NDf ND ND ND ND ND 
6.67 17.5 10.5 11.1 8.4 'i'6 6.2 18.0 22.0 11.0 ND ND ND ND ND ND 
7 8.4 12.4 12.5 10.5 10.4 12.5 6.4 6A 7.4 3.1 5 5.3 6.1 5.8 5.2 
8 4 4.8 7.8 5.5 5.1 12.3 8.5 14.1 7.5 5 4 17 6.3 8 8.2 
9 3.7 2.9 2.9 3.8 1.8 10.5 4.1 1.6 5.6 0.3 5 4.5 1.8 0.5 2.8 
10 1.1 1.1 0.7 1.9 0.6 4.4 0.6 0.6 0.7 3.8 1 0.2 2.7 1 4.2 
11 1.1 0.7 0.3 1.5 1.1 2.1 0.6 0.8 1.6 0.3 3 0.2 4.3 0.3 5.3 
12 0.7 1.1 2.5 3.1 2.5 2.1 2.9 1.7 3.7 7.4 4 0.2 6.5 1 3.3 
13.1 3 6.1 4 4 4.5 4.2 5.5 5.0 3.1 4.1 5.8 2 8.6 4 4.8 
13.23 6 '3 2.9 3.8 2.5 5.1 3.6 2.6 2.2 4.2 6 0.5 4.6 7.1 4 
14 2 5 4.1 4.6 4.5 4.2 4.9 4.8 1.9 14 4 1.5 5.3 7 6.8 
15 1.7 1.3 1.8 1.6 0.8 1.4 0.9 2.6 0.4 5.2 2 2.9 1.8 1 3.1 
16 0.3 0.7 2 1 0.4 1.2 1.0 1.1 0.5 4.6 1 1.8 1.7 1 2.3 
17 1.5 3.5 1.8 1.5 1.2 1.4 3.1 0.8 2.0 3 2 2.3 2.4 2 4.3 
18 0.3 1.4 1.9 1.7 1.4 1.4 1.5 0.8 0.9 0.3 1 5 2.7 2 3 
19 0.4 1.4 0.5 1.4 1.6 0.5 0.6 0.7 0.2 0.2 0.3 5 4.6 1 5.6 
20 0.5 1 1.9 2 1.4 0.5 0.6 0.7 0.8 0.3 0.2 6 1.1 1 3 
21 1 0.3 1.6 0.7 0.7 0.3 0.3 0.5 0.4 ND ND ND ND ND ND 
22 0.3 0.5 1 0.4 0.4 0.2 0.1 0.3 0.1 ND ND ND ND ND ND 
23 0.5 0.3 1.8 0.4 0.3 0.5 0.4 0.5 0.1 ND ND ND ND ND ND 
24 0.3 0.2 0.8 0.7 0.3 0.5 0.3 0.9 0.1 ND ND ND ND ND ND 
• Values shown in this table are percentages of cpm present in correspondent Vp of the tota! cpm present in the repertoire surveyed. 
• Vp5.23 = Vp5.2/5.3; Vp6.1234 = Vp6.1/6.2/6.3/6.4; Vp6.589 = Vp6.5/6.8/6.9; Vp6.67 = Vp6.6/6.7; VP13.23 = VP13.2/13.3. 
, NS, uninvolved skin. 
, Underline, Vp families in uninvolved skin representing more than 5% of the total repertoire and greater than 2% higher compared with PBMe from the same patient . 
• Bold, Vp families in lesions representing more than 5% of the total repertoire and greater than 2% higher compared with PBMe from the same patient. 
IND, not done. 
Table ill. TCR Vp Family Repertoire in Squamous Cell Carcinoma Patients' 
Patients 
L M N 0 P Q R 
v/1 Lesion PBMC Lesion PBMC Lesion PBMC Lesion PBMC Lesion PBMC Lesion PBMC Lesion PBMC 
1 1.5 1.6 1.8 2.4 2.5 5.0 0.2 2.8 0.2 0.4 2.2 9.5 4.8 2.9 
2 2.3 1.5 0.5 0.4 0.5 1.6 1.2 3.8 1 1 6.5 13.8 11.5 8.5 
3 11.6' 2.7 1.4 2.4 1.8 5.3 3.0 4.6 5.7 8.3 12.9 4.7 5 8.7 
4 14.8 4.2 6.4 7.9 1.2 13.8 2.9 9.2 3.1 6.4 8.9 5.8 4.7 10.9 
5.1 3.9 5.5 13.2 5.5 5.9 6.8 14.3 2.0 3.9 3.3 4.7 9.1 5 9.7 
5.23 0.9 2.2 1.6 1.2 2.5 3.3 2.2 2.0 1.4 1.2 1.2 4.3 3.9 5.2 
6.1234 2.1 2.8 2.1 2.2 10.4 1.7 9.0 5.6 10.2 4.4 10.5 10.3 13.4 13.3 
6.589 5.5 10.4 14.2 16.9 16.5 9.2 4.8 11.8 6.1 7.8 NDJ ND ND ND 
6.67 6.8 10.0 16.9 14.6 20.8 16.9 18.7 12.8 18.9 16.2 ND ND ND ND 
7 4.6 7.6 8.1 9.7 8.4 10.4 7.5 6.7 5.7 15.5 2.8 11.1 15.9 7.8 
8 14.3 7.1 7.2 9.8 5.2 6.2 6.4 6.2 9 4.3 5.9 8.3 8.5 7.8 
9 6.3 5.7 4.5 4.3 3.1 3.0 1.1 6.6 3.3 0.6 3.7 4.6 1.4 1.2 
10 1.6 2.4 1.0 0.7 1.5 0.9 0.2 0.6 2.4 0.3 0.5 0.5 0.2 0.5 
11 0.7 3.4 1.1 1.1 0.3 0.3 0.2 1.8 0.2 0.4 0.7 0.8 2.3 0.8 
12 4.1 4.3 2.2 2.5 0.9 1.4 5.6 1.7 1.3 3.4 7.1 1.3 2.2 2.7 
13.1 5.6 3.6 3.3 2.0 3.1 1.8 8.5 4.8 6 4.7 2 3.6 2.8 3.7 
13.23 2.0 2.3 2.3 2.8 4.5 1.6 1.4 3.3 1.7 8.7 1.3 2.7 2.3 3.5 
14 4.7 3.3 3.6 2.2 2.8 1.9 7.6 3.7 3.9 1.4 17.5 2.1 4.3 2.3 
15 1.4 1.2 0.9 0.6 0.7 0.3 0.8 0.3 1.9 2 7 1.2 4.2 0.6 
16 1.4 2.7 1.2 1.4 1.6 1.0 0.2 0.1 3.3 0.4 1.2 0.6 0.9 0.5 
17 0.7 3.0 3.1 2.8 1.9 2.6 0.3 0.6 1.3 2 1.8 0.9 0.6 2.2 
18 0.5 2.1 1.1 0.8 0.9 0.9 1.0 5.4 2.4 0.6 1 2.6 1.2 1.3 
19 0.0 1.0 0.2 2.3 0.3 0.3 0.3 0.9 2.3 0.3 0.1 0.2 0.3 0.8 
20 0.4 2.9 0.5 1.8 1.0 2.5 0.1 0.1 2.7 0.4 0.7 1.8 4.6 5.6 
21 0.6 0.9 0.3 0.8 0.5 0.5 0.2 0.1 0.3 2.1 ND ND ND ND 
22 0.5 1.3 0.6 0.7 0.7 0.2 1.9 1.5 0.8 1.8 ND ND ND ND 
23 0.6 3.9 0.2 0.1 0.3 0.2 0.4 0.5 0.5 0.8 NO NO NO NO 
24 0.7 0.4 0.3 0.2 0.4 0.2 0.2 0.6 0.7 0.3 ND ND ND ND 
• Values shown in this table are percentages of cpm present in correspondent Vp of the total cpm present in the repertoire surveyed. 
• Vp5.23 - Vp5.2/5.3; Vp6.1234 - Vp6.1/6.2/6.3/6.4; Vp6.589 = VP6.5/6.8/6.9; Vp6.67 = Vp6.6/6.7; VP13.23 = Vp13.2/13.3 . 
• Bold, Vb families in lesions representing more than 5% of the total repertoire and greater than 2% higher compared with PBMe from the same patient. 
• NO, not done. 
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Table IV. TCR Vp Family Repertoire in Squamous Cell Carcinoma Patients, Including Analysis of Uninvolved Skina 
Patients 
L 0 M P 
vfJ' Lesion NS' PEMe Lesion NS PEMe Lesion NS PEMe Lesion NS PEMe 
1 1.5 0.3 1.6 0.2 1.9 2.8 1.8 1.4 2.4 0.2 1.6 0.4 
2 2.3 0.6 1.5 1.2 5.2d 3.8 0.5 0.6 0.4 1 1.4 1 
3 11.6' 5.3 2.7 3.0 4.8 4.6 1.4 2.6 2.4 5.7 8. 1 8.3 
4 14.8' 20.6 4.2 2.9 3.5 9.2 6.4 7.4 7.9 3.1 1.2 6.4 
5.1 3.9 6A 5.5 14.3 5.5 2.0 13.2 5.9 5.5 3.9 3.1 3.3 
5.23 0.9 0.5 2.2 2.2 1.2 2.0 1.6 1.3 1.2 1.4 1.6 1.2 
6.1234 2.1 1.3 2.8 9.0 2.3 5.6 2.1 1.6 2.2 10.2 9.9 4.4 
6.589 5.5 12.3 10.4 4.8 4.3 11.8 14.2 9.8 16.9 6. 1 8.7 7.8 
6 .67 6.8 T2 10.0 18.7 19.1 12.8 16.9 23.3 14.6 18.9 17.8 17.2 
7 4.6 7.2 7.6 7.5 9.5 6.7 8.1 D 9.7 5.7 7.2 15.5 
8 14.3 17.8 7.1 6.4 7.5 6.2 7.2 7.4 9.8 9 7 4.3 
9 6.3 5.9 5.7 1.1 2.6 6.6 4.5 3.5 4.3 3.3 3.9 0.6 
10 1.6 1.3 2.4 0.2 1.1 0.6 1.0 1.1 0.7 2.4 1.3 0.3 
11 0.7 1.1 3.4 0.2 0.7 1.8 1.1 8.4 1.1 0.2 0.2 0.4 
12 4.1 2.9 4.3 5.6 2.1 1.7 2.2 1.8 2.5 1.3 1.6 3.4 
13.1' 5.6 1.9 3.6 8.5 11.2 4.8 3.3 3.2 2.0 6 4.4 4.7 
13.23 2.0 0.9 2.3 1.4 T6 3.3 2.3 1.9 2.8 1.7 3.9 8.7 
14 4.7 1.4 3.3 7.6 6.8 3.7 3.6 3.0 2.2 3.9 4.1 1.4 
15 1.4 0.5 1.2 0.8 0.7 0.3 0.9 0.8 0.6 1.9 3.2 2 
16 1.4 0.6 2.7 0.2 1.0 0.1 1.2 0.9 1.4 3.3 3.5 0.4 
17 0.7 0.8 3.0 0.3 0.4 0.6 3.1 1.3 2.8 1.3 0.4 2 
18 0.5 0.4 2.1 1.0 1.1 5.4 1.1 1.1 0.8 2.4 1.2 0.6 
19 0.0 0.6 1.0 0.3 0.3 0.9 0.2 0.7 2.3 2.3 2.4 0.3 
20 0.4 0.7 2.9 0.1 1.3 0.1 0.5 2.0 1.8 2.7 0.8 0.4 
21 0.6 0.4 0.9 0.2 0.3 0.1 0.3 0.7 0.8 0.3 0.3 2.1 
22 0.5 0.7 1.3 1.9 0.4 1.5 0.6 0.4 0.7 0.8 0.3 1.8 
23 0.6 0.2 3.9 0.4 0.4 0.5 0.2 0.1 0.1 0.5 0.3 0.8 
24 0.7 0.2 0.4 0.2 0.5 0.6 0.3 0.1 0.2 0.7 0.3 0.3 
• Values shown in this table arc percentages of cpm present in correspondent vp of the total cpm present in the repertoire surveyed. 
• VpS.23 = VpS.2/S.3; Vp6.1234 = Vp6.1 /6.2/6.3/6.4; Vp6.S89 = Vp6.S/6.8/6.9; Vp6.67 = Vp6.6/6.7; VP13.23 = Vp1 3.2/13.3. 
J Underlined, Vp families in uninvolved ski n representing morc than 50/0 of the total rcpcrtoil"c and greater than 2% higher compa.red w ith FBMe frol11 the same patient. 
• Bold, Vp fami lies in lesions representing greater than S% of the total repertoire and more than 2% higher compared with PBMC from the same patient. 
pared with PBMC (Table III). Although no Vp family was over-
represented in all of the SCC studied, Vp6.1 -6.4 and Vp6.6/6.7 
were overrepresented in SCC versus PBMC of three of seven and 
four of seven donors, respectively. 
Simultaneous analysis of the TCR repertoire in SCC versus 
PBMC and uninvolved skin from the same donor further revealed 
Vpskewing in all four donors studied (Table IV). In patient L, Vp3 
and Vp13.1 were overrepresented in SCC; in patient 0, VpS.1, 
Vp6.1-6.4, and VP12 were overrepresented in SCC; in patient M, 
VpS .1 and in patient P, Vp8 were overrepresented in see. The 
number of V p families that are predominant in SCC was diminished 
by the simultaneous comparison w ith uninvolved skin, again sug-
gesting that the res ident T-cell population in skin influences the 
inflammatory response to skin cancer. 
TCR Vp Repertoire in Uninvolved Skin The analysis of the 
TCR Vp repertoire in uninvolved skin from SCC and BCC patients 
provided an opportunity to compare the TCR repertoire in unin-
v olved skin versus PBMC and hence determine whether specific 
T -cell populations reside in skin. As summarized in Table V, sev-
eral Vp families frequently were overrepresented in the uninvolved 
samples studied. For example, V p6.1 - 6.4 were overrepresented in 
six of the nine samples studied, and Vp6.6/6.7 was overrepresented 
in four of nine uninvolved skin samples studied. VP2, VP3, Vp6.S/ 
6.8/6.9, VP8, Vp13.1, and Vp13.2/13.3 were overrepresented in 
three of nine uninvolved skin samples. In general, the overrepre-
sented T-cell populations in uninvolved skin differed from individ-
ual to individual. 
DISCUSSION 
The identification of T-cell populations that may mediate anti-tu-
mor immune responses is a fundamental goal of cancer research. It is 
possible to define the T -cell populations that infiltrate in and 
around tumors according to the diversity of their TCR repertoire. 
By measunng TCR V gene usage, investigators have shown that a 
smal~ number of TCR subpopulations represent a large percent of 
TIL tn cancer, suggesting recognition of a small number of tumor-
sp~cific antigens [14 - 17]. In the case of melanoma, the TCR reper-
toire of TIL has not been compared to the resident skin T cell 
repertoire [18] . The present study was designed to identify specific 
T-cell subpopulations that infiltrate BCC and SCC relative to 
PB~C and the resident skin T-cell pool. Because the majority of 
TIL tn BCC and SCC bear ap TCRs, we investigated V p gene usage 
by PCR. The results of this analysis indicate selective overrepresen-
tatlon of a small number of V p fami lies in TIL of BCC and SCC 
compared to both PBMC and the resident population in uninvolved 
skin. 
The characterization of T cells in the local immune response to 
skin cancer has been an active area of investigation. The percentages 
of CD4+ and CD8+ T cells have been evaluated by immunohisto-
logy, and most studies have indicated that CD4+ cells predominate 
in the infiltrate in and around BCC and SCC tumors, although the 
ratio of CD4+ to CD8+ cells is similar to PBMe [19] . Infiltrating 
T cells express interleukin-2R and human leukocyte antigen DR, 
which provides evidence for activation [20]. One of the most critical 
determinants on the cell surface of T cells is the TCR, which is 
required for antigen recognition. The present study examined 
whether specific populations of T cells accumulate in Bec and 
SCC on the basis of Vp usage, a measure of TCR diversity. We 
found that PCR analysis of V p gene usage showed skewing of the 
Vp repertoire in BCC and SCC compared to the PBMC of the same 
individuals. One or more Vp families represented at least 5% of the 
repertoire in TIL and was overrepresented by at least 2% in TIL 
compared with PBMe. Carefu l analysis of our PCR technique 
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Table V. Predominant Vp Families in Uninvolved Skin" 
Patients vp Families Overrepresented in Uninvolved Skin 
BCC-C 
BCC-E 
BCC-G 
BCC-J 2 
BCC-K 2 
SCC-L 
SCC-O 2 
SCC-M 
SCC-R 
Total! 3/9 
3 
3 
3 
3/9 
4 
4 
2/9 
5.1 
1/9 
6.1 
6.1 
6.1 
6.1 
6.1 
6.1 
6/9 
6.5 
6.5 6.6 
6.6 
6.5 
6.6 7 
6.6 
3/9 4/9 1/9 
8 
8 
11 
8 
3/9 1/9 
13.1 
13.1 
13.1 
3/9 
13.2 
13.2 
13.2 
3/9 
• The numbers indicate the overrepresented Vp families in uninvolved skin compared to PBMe. 
b Sum for the most common overrepresented Vp subfamily groups in uninvolved skin. 
indicates these differences to be meaningful. Therefore, the data 
indicate that several TCR subpopulations are dominant in TIL of 
BCC and SCC compared with PBMe. 
In five individuals with BCC and four individuals with SCC, we 
determined simultaneously the Vp repertoire of uninvolved skin to 
assess more critically whether specific TCR populations are present 
in TIL. Some of the TCR Vps that were overrepresented in TIL 
compared to PBMC similarly were overrepresented in the unin-
volved skin. However, in seven of the nine patients, one or more V p 
families were found to represent at least 5% of the repertoire in TIL 
and were overrepresented by at least 2% compared with both 
PBMC and uninvolved skin. We believe that the present data are 
novel in demonstrating specific T-cell populations that are rela-
tively overrepresented in TIL compared to both PBMC and unin-
volved tissue. 
The most likely explanation for the localization of specific Vp 
populations to BCC lesions is the recognition of a small number of 
antigens, perhaps tumor-specific antigens. BCC are derived from 
keratinocytes, and some studies have indicated antigen differences 
between tumor cells and normal keratinocytes. For example, the 
pattern of expressed keratins in BCC may be different compared 
with normal keratinocytes of the basal layer [21,22]. Similarly, SCC 
exhibits altered keratin composition indicative of differences in ke-
ratinocyte maturation and differentiation [23,24]. In addition, large 
or metastatic SCC has been associated with elevation in serum levels 
of SCC-related antigens [25]. Another possibility is autologous an-
ti gen expression by keratinocytes. For example, heat shock proteins 
are known to be produced on keratinocytes, and such a protein may 
be targets of the T-cell response [26J. 
The observed variation in the predominant V p gene usage from 
individual to individual is likely to be due, in part, to differences in 
polymorphic major histocompatibility complex molecules, as Vp 
gene usage is influenced by the combination of antigen and major 
histocompatibility complex haplotype of the individual [27,28]. 
The identification of the antigens recognized by TIL in BCC and 
SCC and the correlation of TCR V gene usage with major his to-
compatibiliry complex molecules and other T-cell determinants 
should provide insight into the mechanism ofTCR selection in skin 
cancer. 
A noteworthy finding was the skewed repertoire in the unin-
volved skin when compared to peripheral blood. Although we 
noted that VP3, Vp6.1 - 6.4, and Vp6.6/6.7 were overrepresented 
in about half of all the tumors compared to PBMC, these Vps were 
found to be overrepresented in some of the uninvolved skin. Fur-
thermore, we found that VP2, VP6.5/6.8/6.9, VP8, and Vp13.1 
were overrepresented in several of the normal skin samples studied. 
These data confirm those of Dunn et al [29J in finding a skewed Vp 
repertoire of the resident T-cell compartment in skin. However, in 
contrast to our findings, Dunn et al [29] reported that in their normal 
skin, mostly obtained from patients with lichen planus, VPl, VP7, 
VP14, and VP16 were overrepresented in most of the donors stud-
ied. It will be important to characterize the Vp repertoire in normal 
skin from completely healthy donors. 
There is a sparse resident population in normal human skin com-
posed of TCR ap and yJ T-cells [18]. In human skin there is a 
somewhat restricted V J gene usage [30]. although it is not as limited 
as the yJ TCR repertoire of mouse epidermis [31]. Other human 
epithelial surfaces such as gut express a limited TCR Vp repertoire 
[32,33]' These resident T-cell populations may form a first line of 
defense against infectious pathogens and neoplastic changes. It will 
be important to determine the roles of the overrepresented T-cell 
populations in BCC and SCC, as well as the resident T-cell popula-
tions in skin, in mediating anti-tumor immunity. 
This work was supported by grallts from tile Natiollal [lIStitutes oj Health (AI 
22553, AR 40312, AI28508), Natiollal Callcer Itlstitute (CA 56860), alld tile 
Dermatology Researcil Foulldatioll oj Califortlia, [II C. We are gratifuI to Drs. Mitcil-
ell Krolletlberg, Jor scietltijic discussiolls, and Haroot DerSimolliall, Jor the Vp alld 
Cp oligOllUcleotide sequences. 
REFERENCES 
1. Habets JMV, Tank B, Vuzevski VD, van Reede EC, Stolz E, van Joost T : Charac· 
terization of the mononuclear infiltrate in basal cell carcinoma: a predominately 
T cell-mediated immune response with minor participation ofLeu-7+ (natural 
killer) cells and Leu-I4+ (B) cells.] blVest DermatoI90:289-292, 1988 
2. Curson C, Weedon 0: Spontaneous regression in basal cell carcinomas.] Curall 
PathoI6:432-437,1979 
3. Brown FC. Tan EM: Immunological reaction in keratoacanthoma, a spontane-
ously resolving skin tumor. Callcer R es 33:2030-2033,1973 
4. Cornell RC. Greenway HT, Tucker SB, Edwards L, Ashworth S. Vance JC. 
Tanner OJ, Taylor EL. Smiles KA. Peets EA: Intralesional interferon therapy 
for basal cell carcinoma.] Am Aead Dermatol23:694 - 700, 1990 
5. Mozzanica N, Cattaneo A. Boneschi V. Brambilla L. Melotti E. Finzi AF: Im-
munohistological evaluation of basal cell carcinoma immunoinfiltrate during 
intralesional treatment with alpha 2-interferon. Arch Dermatol R es 282:311-
317, 1990 
6. Tank B, Habets JM, Naafs B, Damsma 0, Stolz E, van Joost T: Intralesional 
treatment of basal cell carcinoma with low-dose recombinant interferon 
gamma.] Am Aead Derlllato/21 :734-735. 1989 
7. Greenway HT, Cornell RC, Tanner OJ. PeetsE, Bordin GM, Nagi C: Treatment 
of basal cell carcinoma with intralesional interferon.] Am Aead Dermatol 
15:437 -443.1986 
8. Ikic 0, Padovan I, Brodarec M. Soos E: Application of human leukocyte inter-
feron in patients with tumOrs of the head and neck. Lao"et I: 1025-1027,1981 
9. Wickramasinghe L, Hindson TC. Wacks H: Treatment of neoplastic skin lesions. 
] Alii A ead DerlllatoI20:74- 79, 1989 
10. Hartevelt MM, Bavinck IN. Kootte AMV. Vermeer BJ, Vandenbroucke JP: 
Incidence of skin cancer after renal transplantation in The Netherlands. Tram-
plalltalioll 49:506 - 509, 1990 
11. Gupta AK, Cardella CJ, Haberman HF: Cutaneous malignant neoplasms in pa-
tients with renal transplants. Arch DerlllatoI122: 1288-1293, 1986 
12. Chomczynski P, Sacchi N: Single-step method ofRN A isolation by acid guanidi-
nium thiocyanate-phenol-chloroform extraction. Allal Bioe/lfln 162:156-159, 
1987 
13. DerSimonian H, Band H , Brenner MB: Increased frequency ofT cell receptor V 
alpha 12.1 expression on CD8+ T cells: evidence that V alpha participates in 
shaping the peripheral T cell repertoire.] Exp Med 174:639-648. 1991 
14. Nitta T, OksenbergJR, Rao NA. Steinman L: Predominant expression ofT cell 
receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. 
Sciell ce 249:672-674,1990 
. ' 
VOL. 103. NO.6 DECEMBER 1994 T CELLS IN SKIN CANCER 757 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
Nitta T . Bell R. Okumura K. Sato K. Steinman L: T-cell receptor V beta gene 
expression differs in tumor-infiltrating lymphocytes within primary and meta-
static melanoma. Callcer Res 51 :5565 -5569. 1991 
Nitta T. Sato K. Okumura K. Steinman L: An analysis ofT-ceil-receptor variable-
region genes in tumor-infiltrating lymphocytes within malignant tumors. [IIIJ 
Callcer 49:545-550.1991 
Ferrandini L. Roman-Roman S. Azocar J. Avril M. Viel S. Triebe! F. Hercend T: 
Analysis ofT-cell receptor alpha/beta variability in lymphocytes infiltrating a 
melanoma metastasis. Callcer Res 52:4649 - 4654.1992 
Groh V. PorcelliS. Fabbi M. Lanier L. Picker LJ. Anderson T . Warnke RA. Bhan 
AK. Strominger JL. Brenner MB: Human lymphocytes bearing T cell receptor 
gamma / delta are phenotypically diverse and evenly distributed throughout the 
lymphoid system.] Exp Med 169:1277 -1294. 1989 
Eaglestein NF. Hernandez AD. Allen JE: Lymphocytic response to basal cell 
carcinoma: in situ identification of functional subsets using monoclonal anti-
bodies. ] Dermalol SlIrg 011<0/8:943-947.1982 
Hunt MJ. Halliday GM. W eedon D. Cooke BE. Barnetson RS: Regression in 
basal cell carcinoma: an immunohistochemical analysis. Br J Dmnalo/130:1 - 8. 
1994 
Shimizu N . Ito M. Tazawa T. Sato Y: Immunohistochemical study on keratin 
expression in certain cutaneous epithelial neoplasms. Basal cell carcinoma. 
pilomatricoma. and seborrheic keratosis. A m J Dermalopal/IOI 11 :534-540. 
1989 
Markey AC. Lane EB. MacDonald OM. Leigh 1M: Keratin expression in basal cell 
carcinomas. Br] Dermalo/126:154 - 160. 1992 
Viac J . Reano A. Thivolet J : Cytokeratins in human basal and squamous cell 
carcinomas: biochemical. immunohistological findings and comparisons with 
normal epithelia.] C,lia II Palho19:377 -390. 1982 
Robinson JK: Expression of keratin proteins in deeply invasive basal and squa-
mous cell carcinoma: an immunohistochemical study. J Dennalol SlIrg 011<01 
13:283-294. 1987 
25. Yagi H. Danno K. Maruguch i Y. Yamamoto M. Imamura S: Significance of 
squamous cell carcinoma (SCC)-re!ated antigens in cutaneous SCc. A rdl Der-
ma IO/1 23:902-906. 1987 
26. Mehra V. Bloom BR. Bajardi AC. Grisso CL. Sieling PA. Alland D. ConvitJ. Fan 
XD. Hunter SW. Brennan PJ. Rea TH. Modlin RL: A major T cell antigen of 
MYloba£lerillm leprae is a 10-kD heat-shock cognate protein. ] Exp Med 
175:275 -284. 1992 
27. Morel PA. Livingstone AM. Fadunan CG: Correlation ofT cell receptor Vb gene 
fa mily with MHC restriction.] Exp Med 166:583 - 588. 1987 
28. Gulwani-Akolkar B. Posnett DN.Janson CH. GrunewaldJ . Wigzell H. Akolkar 
p. Gregersen DK. Silver J : Tcell receptor V-segment frequencies in peripheral 
blood T cells correlate with human lenkocyte antigen type. J Exp Med 
174:11 39- 1146.1991 
29. Dunn DA. Gadenne A. Simha S. Lerner EA. Bigby M. Bleicher PA: T-cell 
receptor V-beta expression in normal human skin. PrOl Nail Acad Sci USA 
90:1267-1271 . 1993 
30. Uyemura K. Deans RJ. Band H. OhmenJ. Pancharnoorthy G. Morita CT. Rea 
TH. Modlin RL: Evidence for clonal selection of gamma/delta T -cells in 
response to a human pathogen.] ExpMed 174:683-692. 1991 
31 . Tigelaar RE. Lewis JM. Bergstresser PR: TCR gamma / dclta+ dendritic epider-
mal T cells as constituents of sk in-associated lymphoid tissue.J [llvesl Dermalol 
94:58S-63S.1990 
32. Balk SP. Ebert EC. Blumenthal RL. McDermott FV. Wucherpfennig KW . lan-
dau SB. Blumberg RS: Oligoclonal expansion and CDI recognition by human 
intestinal intraepithclial lymphocytes. Seie,,,e 253:1411 - 1415. 1991 
33. Van Kerckhove C. Russel GJ . Deusch K. Reich K. Bhan AK. DerSimonian H. 
Brenner MB: Oligoclonality of human intestinal intr.epithelial T cells.] Exp 
Med 175:57 - 63. 1992 
ANNOUNCEMENT 
The European Society of Dermatological Research Clinically Oriented Symposium, "Vitamin 
D: Actions and Applications in Dermatology" will be held April 27 -29, 1995 in Aarhus, 
Denmark. 
The international symposium is intended to bring together investigators interested in both 
basic science and clinical medicine. The program will include invited speakers for introductory 
lectures as well as free communications (oral and poster presentations) . Selected papers from the 
symposium will be rublished in the Jourtlal of Investigative Dermatology . 
. The progra.m w~l include the biology ~f vitamin D.; eXRression, regulation, .and gene regula-
tion of the vltamm D receptor; photobiology of Vltamm D, role of cytokmes and growth 
factors; immunomodulatory role (lymphocytes, macrophages, Langerhans cells); cell differen-
tiation and photobiology; clinical experience with vitamin D analogs; clinical tolerability and 
safety; and potential use in lymphomas and carcinomas. 
The organizing secretariat includes Knud Kragballe (Denmark), Thomas Krieg (Germany), 
Karsten Fogh (Denmark), Christian Gr0nh0j Larsen (Denmark), John J. Voorhees (USA), 
Jean-Hilaire Saurat (Switzerland), Daniel Bikle (USA), Peter van de Kerkhof (The Nether-
lands), Michael Holick (USA) , and Klaus Bendtsen (Denmark) . 
For information contact Knud Kragballe, MD, PhD, Department of Dermatology, Marselis-
borg Hospital, DK-8000 Aarhus C, Denmark. Tel. +45 89 49 1856; Fax +458949 1870. 
